The Trump administration plans to announce on Monday agreements with several midsized biotechnology companies to reduce outpatient drug prices for state Medicaid programs, aligning U.S. reimbursement rates with lower prices paid in foreign markets.
Under the proposed deals, companies will voluntarily offer discounts on certain drugs to Medicaid, while gaining exemption from federal pilot programs that would otherwise mandate similar rebates in Medicare. Some discussions also include relief from tariffs as part of the negotiations, according to sources cited by Bloomberg.
Participation by state Medicaid programs remains optional, and the specific drugmakers involved have not been disclosed. The White House has framed the initiative as part of broader efforts to lower prescription costs for American patients, with spokesman Kush Desai stating the administration is making progress on "most-favored-nations deals" to cut drug expenses.
Analysts noted that Medicaid already receives statutory discounts from manufacturers, and many low-income or disabled beneficiaries face minimal out-of-pocket costs for prescriptions. The financial impact of the agreements on federal spending or patient savings has not been quantified, leaving uncertainty about the scope of potential benefits.
